Caplacizumab

卡拉西珠单抗

Report date: 2025/11/17 14:55:47
First In Class

Base Information

Drug NameCaplacizumab
Drug Alias Name卡拉西组单抗Caplacizumab-YHDP卡普赛珠单抗Anti-vWF nanobodyCaplacizumabum +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionVon willebrand factor inhibitors
TargetsVon willebrand factor
Therapy Area/IndicationsAcquired thrombotic thrombocytopenic purpuraPurpura, Thrombotic ThrombocytopenicNon-ST Elevated Myocardial Infarction +[4] 
Global Approved IndicationsAcquired thrombotic thrombocytopenic purpuraPurpura, Thrombotic Thrombocytopenic
Approved Indications in ChinaAcquired thrombotic thrombocytopenic purpura
Original Approved Country/TerritoryEU
Original Approved Date2018/08/30
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesSanofi KkAblynx Nv
Inactive CompaniesSanofi
Active IndicationsAcquired thrombotic thrombocytopenic purpuraPurpura, Thrombotic Thrombocytopenic
Inactive IndicationsNon-ST Elevated Myocardial InfarctionAngina, Unstable

Other Information

ATC CodeB01AX07
Related LinksWikipediaDrugBankKEGG